Orbimed Advisors LLC Travere Therapeutics, Inc. Transaction History

Orbimed Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$15.3 - $22.61 $5.72 Million - $8.45 Million	373,800 Added 21.43%	2,118,100 $32.5 Million
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $8.75 Million - $11.2 Million	491,170 Added 39.2%	1,744,300 $39.2 Million
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $11 Million - $13.8 Million	480,930 Added 62.28%	1,253,130 $30.9 Million
Q2 2022 Aug 15, 2022	BUY	$20.94 - $30.01 $16.2 Million - $23.2 Million	772,200 New	772,200 $18.7 Million
Q2 2021 Aug 16, 2021	SELL	$14.11 - $26.4 $7.45 Million - $13.9 Million	-528,100 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$23.37 - $31.77 $12.3 Million - $16.8 Million	528,100 New	528,100 $13.2 Million

196

84.9M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.